Navigation Links
Peptide being tested to treat atherosclerosis inhibits ovarian cancer growth
Date:11/1/2010

A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

The study follows previous discovery by the same group showing that a protein called apolipoprotein A-I (apoA-I) in patients may be used as a biomarker to diagnose early stage ovarian cancer, when it typically is asymptomatic and is much easier to treat. These earlier findings could be vital to improving early detection, as more than 85 percent of ovarian cancer cases present in the advanced stages, when the cancer has already spread and patients are more likely to have a recurrence after treatment, said Dr. Robin Farias-Eisner, chief of gynecologic oncology and co-senior author of the study with Dr. Srinu Reddy, a professor of medicine.

"The vast majority of ovarian cancer patients are diagnosed with advanced disease and the vast majority of those, after surgery and chemotherapy, will eventually become resistant to standard therapy," Farias-Eisner said. "That's the reason these patients die. Now, with this peptide as a potential therapy, and if successful in clinical trials, we may have a novel effective therapy for recurrent, chemotherapy-resistant ovarian cancer, without compromising the quality of life during treatment."

The study was published Nov. 1, 2010 in the early online edition of the peer-reviewed journal Proceedings of the National Academy of Sciences.

In their previous work, Farias-Eisner, Reddy and their research teams identified three novel biomarkers that they used to diagnose early stage ovarian cancer. In September 2009, the U.S. Food and Drug Administration cleared the first laboratory test that can indicate the likelihood of ovarian cancer, OVA1TM Test, which includes the three biomarkers identified and validated by Farias-Eisner, Reddy and their research teams.

They observed that one of the markers, apoA-I, was decreased in patients with early stage disease. They wondered why the protein was decreased and set out to uncover the answer. They speculated that the protein might be protective, and may be preventing disease progression.

The protein, apoA-I, is the major component of HDL, the good cholesterol, and plays an important role in reverse cholesterol transport by extracting cholesterol and lipids from cells and transferring it to the liver for extraction. The protein also has anti-inflammatory and antioxidant properties. Because lipid transport, inflammation and oxidative stress are associated with the development and progression of cancer, Farias-Eisner and Reddy hypothesized that the reduced levels of apoA-I in ovarian cancer patients may be causal in disease progression.

Mice that were engineered to have many copies of human apoA-I gene showed very little cancer development when induced with ovarian cancer, while the mice without the extra copies of apoA-I showed much more disease. The mice with extra copies of the apoA-I gene also lived 30 to 50 percent longer than those who didn't receive it.

Farias-Eisner and Reddy wanted to treat the mice that had more cancer with the protein apoA-I, but it was too large to conveniently administer, having 243 amino acids. The researchers then turned to apoA-I mimetic peptides - only 18 amino acids in length - that are being tested for cardiovascular diseases. That project had been ongoing for a number of years at UCLA, said Reddy, who is also a part of the cardiovascular research team led by Dr. Alan M. Fogelman, executive chair of the Department of Medicine.

"The smaller peptides mimic the larger apoA-I protein and provided us with agents we could give to the mouse to see if it was effective in fighting ovarian cancer," said Reddy. "One of the peptides was being tested as an experimental therapy for atherosclerosis, so we already have some information on how it's being tolerated in humans, which would be vital information to have if we progressed to human studies in ovarian cancer."

The peptide, thus far, has caused little to no side effects in atherosclerosis patients, Reddy said, a hopeful sign that it might be well tolerated in ovarian cancer patients.

The mice that were given the peptide by injection had about 60 percent less cancer than the mice that did not receive the peptide, Farias-Eisner said. The peptide also was given in drinking water or in mouse food and proved to be as effective when administered that way.

"It was an exciting result," Farias-Eisner said. "It looked like we had something that could be ingested or injected that might be very effective against ovarian cancer progression."

Farias-Eisner said the peptide avidly binds oxidized lipids, one of which is known to stimulate cancer cells to survive and multiply. In the mouse studies, the mice that received peptide had significantly lower levels of this cancer promoting lipid.

An early phase clinical trial is being planned testing the peptide in patients with aggressive ovarian cancers that are resistant to chemotherapy, a group of patients whose median survival is just 40 months. Farias-Eisner hopes the study will be started and completed within two years.


'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Cosmetic Peptides that Significantly Reduce Length and Depth of Wrinkles: Janet Sartin Introduces Advanced Anti-Wrinkle Peptide Serum for All Skin Types
2. Hearts of Hospice Patients Being Needlessly Shocked
3. The Chopra Center for Wellbeing Launches “Manifest the Life You Deserve”
4. Stop Ripping Me Off! Is the Title of a New Consumer Protection Book Being Released Today
5. Being Active an Hour a Day Puts Brakes on Weight Gain
6. New mums beat the blues and increase wellbeing with physio exercise, study reveals
7. New Breast Cancer Book Offers Humor Filled Look at Being Thirty-Something, Single And Getting Through Diagnosis
8. Being Blinded By Jealousy Can Be Real
9. American Human Development Project Releases 'A Century Apart,' Revealing Alarming Disparities in Well-Being Among U.S. Racial and Ethnic Groups
10. Being obese can attract bullies
11. Is Fear of Being Caught Naked an Obstacle to Increasing Breastfeeding Rates?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... TransWipe Volume 3 is a set of 30 professional ... TransWipe preset between two video clips to instantly add a unique transition to any ... customizable color and orientation options. TransWipe Volume 3 is a Final Cut Pro X ...
(Date:5/5/2016)... ... 2016 , ... The U.S. Food and Drug Administration today ... submit their products through an arduous federal approval process. The rules, which treat ... market since February 15, 2007. That would essentially ban 99 percent of all ...
(Date:5/5/2016)... ... May 05, 2016 , ... Spring Fertility , the ... and with egg freezing, today announced the grand opening of its first location ... care, Spring Fertility offers both fertility preservation (egg, sperm, embryo, and testicular and ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Derrin Doty Group ... families of Bremerton, Port Orchard and communities west of Seattle. The insurance provider’s caring ... year local girl who died suddenly due to complications from the flu, that they ...
(Date:5/5/2016)... ... May 05, 2016 , ... A recent survey by the ... challenges in getting employees to understand and use the free preventive care benefits available ... leading non-profit business groups of large, self-insured public and private employers, MBGH found that ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... -- Research and Markets has announced the addition of ... Markets"  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... current Positron Emission Tomography (PET) scanner and cyclotron install base ... France , Germany , ... and the United Kingdom . Along with ...
(Date:5/5/2016)... 5, 2016 Research ... "Europe Systemic Lupus Erythematosus Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Europe Systemic Lupus Erythematosus Market and Competitive ... into Systemic Lupus Erythematosus pipeline products, Systemic ...
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 ... BVXV) announced today that BiondVax,s CEO, Dr. Ron Babecoff ... in New York City . ... 10:30am at Pioneers 2016, a conference presented by Joseph ... Palace Hotel. The BiondVax presentation that Dr. Babecoff ...
Breaking Medicine Technology: